Carl Schwalbe

Dr Carl H. Schwalbe received his Ph.D. in 1970 from Harvard University under the supervision of Nobel laureate Professor William N. Lipscomb, studying the crystal structures of linked polyhedral boranes. His interest in applying crystallography to medicinal chemistry was stimulated by two years of postdoctoral research at the Max Planck Institute for Experimental Medicine in Göttingen, Germany, working mainly on the structures of nucleoside analogues. In 1972, he joined the Pharmacy Department at Aston University, subsequently becoming Professor of Medicinal Chemistry in the School of Life and Health Sciences. ​

Carl is interested in applying crystallography to drug discovery and dosage form design, particularly by identifying preferred conformations and preferred modes of intermolecular interaction in groups of related molecules from the CSD or systematic series of original structure determinations. Recent projects have included inter-ionic interactions and mechanical properties of amine salts of carboxylic acid drugs, Fe(III) ligands based on myo-inositol, and hydrogen bonding in hydantoin derivatives. ​

  • Structure and properties of (hydroxy)alkylammonium salts of flurbiprofen, Schwalbe, C. H.; Ramirez, M.; Conway, B. R.; Bache, C. J.; Coles, S. J. and Timmins, P., Trans. Am. Cryst. Assoc., in press.
  • Conformational analysis of the natural iron chelator myo-inositol 1,2,3-trisphosphate using a pyrene-based fluorescent mimic, Mansell, D.; Rattray, N.; Etchells, L.; Schwalbe, C. H.; Blake, A. J.; Torres, J.; Kremer, C.; Bichenkova, E. V.; Barker, C. J. and Freeman, S., Org. Biomol. Chem., 8, 2850-2858, 2010.
  • Conformational Evaluation of Indol-3-yl-N-alkyl-glyoxalylamides and Indol-3-yl-N,N-dialkyl-glyoxalylamides, Mansell, D.; Brandt, S. D.; Nasima, S.; Turvey, N.; Alder, J. F.; Freeman, S. and Schwalbe, C. H., Spectrosc. Lett., 42, 156-166, 2009.
  • Fluorescent probe: complexation of Fe3+ with the myo-inositol 1,2,3-trisphosphate motif, Mansell, D.; Rattray, N.; Etchells, L. L.; Schwalbe, C. H.; Blake, A. J.; Bichenkova, E. V.; Bryce, R. A.; Barker, C. J.; Díaz, A.; Kremer, C. and Freeman S., Chem. Commun., 5161-5163, 2008.
  • Quinols as novel therapeutic agents 2. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents, Berry, J. M.; Bradshaw, T. D.; Fichtner, I.; Ren, R.; Schwalbe, C. H.; Wells, G.; Chew, E.-H.; Stevens, M. F. G. and Westwell, A. D., J. Med. Chem., 48, 639-644, 2005.
  • Hydantoin and hydrogen-bonding patterns in hydantoin derivatives, Yu, F.-L.; Schwalbe, C. H. and Watkin, D. J., Acta Cryst., C60, o713-o716, 2004.​

Contact Information